TrialPharmacogenomics2024

PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar.

Zhaoxu Geng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.